First-line treatment disruption among post-menopausal women with HR+/HER2– metastatic breast cancer: a retrospective US claims study

References

• International Agency for Research on Cancer–Cancer Research UK. World cancer factsheet; 2014. Available at: http://publications.cancerresearchuk.org/downloads/Product/CS_REPORT_WORLD.pdf
   Google Scholar
• Cadoo KA, Fornier MN, Morris PG. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Q J Nucl Med Mol Imaging 2013;57:312-21
   PubMed Web of Science ®Google Scholar
• Metastatic Breast Cancer Network (MBCN). Incidence and incidence rates; MBCN; 2016. Available at: http://www.mbcn.org/incidence-and-incidence-rates/
   Google Scholar
• O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005;10(Suppl 3):20-9
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Breast cancer survival rates, by stage. ACS; 2016. Available at: http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-survival-by-stage
   Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: breast cancer. V1. NCCN; 2016. Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
   Google Scholar
• Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol 2016;34:3069-103
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015;16:25-35
   PubMed Web of Science ®Google Scholar
• Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii11-9
   PubMed Web of Science ®Google Scholar
• Chung CT, Carlson RW. Goals and objectives in the management of metastatic breast cancer. Oncologist 2003;8:514-20
   PubMed Web of Science ®Google Scholar
• Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 2011;29:2144-9
   PubMed Web of Science ®Google Scholar
• Stockler M, Wilcken N, Coates A. Chemotherapy for advanced breast cancer: how long should it continue? Breast Cancer Res Treat 2003;81(suppl 1):S49-S52
   Google Scholar
• Lin NU, Winer EP. Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time. J Clin Oncol 2008;26:1919-21
   PubMed Web of Science ®Google Scholar
• Li N, Hao Y, Kageleiry A, et al. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US. Curr Med Res Opin 2016;32:385-94
   PubMed Web of Science ®Google Scholar
• Costanzo et al. Real-world treatment patterns of everolimus plus endocrine therapy in patients who hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer by line of therapy: a global chart review. 21st ISPOR Annual International Meeting; May 21–25; Washington, DC; 2016
   Google Scholar
• Petracci et al. Comparative effectiveness of everolimus + endocrine therapy vs. endocrine monotherapy among postmenopausal women with HR+/HER2- advanced breast cancer: a multicountry retrospective chart review. AARC Congress; April 16–20; New Orleans, LA; 2016
   Google Scholar
• Finn RS, Martin M, Rugo HS, et al. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). 2016 ASCO Annual Meeting; J Clin Oncol 2016;34(suppl; abstr 507)
   Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016;375:1738-48
   PubMed Web of Science ®Google Scholar
• Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 388:2997-3005
   PubMed Web of Science ®Google Scholar
• Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003;21:588-92
   PubMed Web of Science ®Google Scholar
• Lafeuille MH, Grittner AM, Lefebvre P, et al. Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer. J Manag Care Spec Pharm 2014;20:477-84
   PubMed Web of Science ®Google Scholar
• Swallow E, Zhang J, Thomason D, et al. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2–) breast cancer patients in the United States: 2002–2012. Curr Med Res Opin 2014;30:1537-45
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
   PubMed Web of Science ®Google Scholar
• Brito C, Portela MC, Vasconcellos MT. Factors associated to persistence with hormonal therapy in women with breast cancer. Rev Saude Publica 2014;48:284-95
   PubMed Web of Science ®Google Scholar
• Rashid N, Koh HA, Baca HC, et al. Clinical impact of chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. J Manag Care Spec Pharm 2015;21:863-71
   PubMed Web of Science ®Google Scholar
• Schmidt N, Kostev K, Jockwig A, et al. Treatment persistence evaluation of tamoxifen and aromatase inhibitors in breast cancer patients in early and late stage disease. Int J Clin Pharmacol Ther 2014;52:933-9
   PubMed Web of Science ®Google Scholar
• Richardson LC, Wang W, Hartzema AG, et al. The role of health-related quality of life in early discontinuation of chemotherapy for breast cancer. Breast J 2007;13:581-7
   PubMed Web of Science ®Google Scholar
• Parisi M, Pelletier C, Cherepanov D, et al. The use of real-world data to examine comparative effectiveness research (CER) and treatment patterns in HER2-negative and triple-negative metastatic breast cancer (MBC): a systematic literature review. J Clin Oncol 2017;35(8 suppl):210
   Google Scholar
• Friese CR, Pini TM, Li Y, et al. Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat 2013;138:931-9
   PubMed Web of Science ®Google Scholar
• Hadji P, Ziller V, Kyvernitakis J, et al. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Treat 2013;138:185-91
   PubMed Web of Science ®Google Scholar
• Debled M, Madranges N, Mertens C, et al. First-line chemotherapy for metastatic breast cancer in patients >/=75 years: a retrospective single-centre analysis. Crit Rev Oncol Hematol 2011;80:171-9
   PubMed Web of Science ®Google Scholar
• Schmidt N, Haas G, Mergenthaler U, et al. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors—analysis based on oncology analyzer database. Value Health 2013;16:A418-A9
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Beegle N, Kalberer T, et al. A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting. J Oncol Pharm Pract Offic Publ Int So Oncol Pharm Pract 2015;21:170-7.
   PubMed Web of Science ®Google Scholar
• Zanotti G, Hunger M, Perkins JJ, et al. Treatment patterns and real world clinical outcomes in ER+/HER2– post-menopausal metastatic breast cancer patients in the United States. BMC Cancer 2017;17:393
   PubMed Web of Science ®Google Scholar
• Fontein DB, Klinten Grand M, Nortier JW, et al. Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial. Ann Oncol 2015;26:1254-62
   PubMed Web of Science ®Google Scholar